Technical Analysis for BOLD - Boundless Bio, Inc.

Grade Last Price % Change Price Change
D 9.67 -2.91% -0.29
BOLD closed down 2.91 percent on Friday, May 17, 2024, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Wide Bands Range Expansion -2.91%
Gapped Down Weakness -2.91%
Multiple of Ten Bearish Other 1.47%
Wide Bands Range Expansion 1.47%
Oversold Stochastic Weakness 1.47%
Wide Bands Range Expansion 4.20%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Boundless Bio, Inc. Description

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Rare Diseases Molecular Biology Gene Therapy Muscular Dystrophy Applied Genetics Duchenne Muscular Dystrophy Myotonic Dystrophy Pompe Disease Gene Therapy Products Treatment Of Pompe Disease

Is BOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.24
52 Week Low 8.51
Average Volume 156,873
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 10.03
10-Day Moving Average 9.54
Average True Range 0.99
RSI (14) 42.20
ADX 33.32
+DI 15.66
-DI 22.88
Chandelier Exit (Long, 3 ATRs) 9.67
Chandelier Exit (Short, 3 ATRs) 11.49
Upper Bollinger Bands 11.81
Lower Bollinger Band 8.25
Percent B (%b) 0.4
BandWidth 35.51
MACD Line -0.69
MACD Signal Line -0.80
MACD Histogram 0.1061
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.53
Resistance 3 (R3) 10.55 10.28 10.39
Resistance 2 (R2) 10.28 10.06 10.27 10.34
Resistance 1 (R1) 9.97 9.92 10.13 9.96 10.29
Pivot Point 9.70 9.70 9.78 9.69 9.70
Support 1 (S1) 9.40 9.48 9.55 9.38 9.05
Support 2 (S2) 9.13 9.35 9.12 9.00
Support 3 (S3) 8.82 9.13 8.95
Support 4 (S4) 8.81